Melanoma: the role of surgery in the era of new therapies

Por Mozzillo, Nicola, Ascierto, Paolo A
Publicado em 2014

Adjuvant therapy of melanoma with interferon: lessons of the past decade

Por Ascierto, Paolo A, Kirkwood, John M
Publicado em 2008

Combination therapy: the next opportunity and challenge of medicine

Por Ascierto, Paolo A, Marincola, Francesco M
Publicado em 2011

What have we learned from cancer immunotherapy in the last 3 years?

Por Ascierto, Paolo A, Marincola, Francesco M
Publicado em 2014

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond

Por Ascierto, Paolo A., Marincola, Francesco M.
Publicado no EBioMedicine (2015)

Melanoma: A model for testing new agents in combination therapies

Por Ascierto, Paolo A, Streicher, Howard Z, Sznol, Mario
Publicado em 2010

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application

Por Ascierto, Paolo A, Marincola, Francesco M, Ribas, Antoni
Publicado em 2011

What’s new in melanoma? Combination!

Por Ascierto, Paolo A, Marincola, Francesco M, Atkins, Michael B
Publicado no J Transl Med (2015)

Melanoma: From Research to Treatment

Por Ascierto, Paolo A., Kirkwood, John M., Marincola, Francesco M., Palmieri, Giuseppe
Publicado em 2011

The Role of Optical Radiations in Skin Cancer

Por Ayala, Fabrizio, Palla, Marco, Di Trolio, Rossella, Mozzillo, Nicola, Ascierto, Paolo A.
Publicado em 2013

Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma

Por Hoeller, Christoph, Michielin, Olivier, Ascierto, Paolo A., Szabo, Zsolt, Blank, Christian U.
Publicado no Cancer Immunol Immunother (2016)

Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials

Por Dummer, Reinhard, Schadendorf, Dirk, Ascierto, Paolo A, Larkin, James, Lebbé, Celeste, Hauschild, Axel
Publicado em 2014

Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?

Por Palmieri, Giuseppe, Colombino, Maria, Cossu, Antonio, Marchetti, Antonio, Botti, Gerardo, Ascierto, Paolo A.
Publicado no J Transl Med (2017)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

Por Ascierto, Paolo A, Simeone, Ester, Giannarelli, Diana, Grimaldi, Antonio M, Romano, Anna, Mozzillo, Nicola
Publicado em 2012

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations

Por Gentilcore, Giusy, Madonna, Gabriele, Mozzillo, Nicola, Ribas, Antoni, Cossu, Antonio, Palmieri, Giuseppe, Ascierto, Paolo A
Publicado em 2013

Lean oncology: a new model for oncologists

Por Montesarchio, Vincenzo, Grimaldi, Antonio Maria, Fox, Bernard A, Rea, Antonio, Marincola, Francesco M, Ascierto, Paolo A
Publicado em 2012

Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma

Por Mozzillo, Nicola, Caracò, Corrado, Mori, Stefano, Di Monta, Gianluca, Botti, Gerardo, Ascierto, Paolo A, Caracò, Corradina, Aloj, Luigi
Publicado em 2012

The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer

Por Daniele, Bruno, Sangro, Bruno, Petrylak, Daniel, Calabrò, Fabio, Cartenì, Giacomo, Montesarchio, Vincenzo, De Placido, Sabino, Ascierto, Paolo A.
Publicado no J Immunother Cancer (2016)

The immune score as a new possible approach for the classification of cancer

Por Galon, Jérôme, Pagès, Franck, Marincola, Francesco M, Thurin, Magdalena, Trinchieri, Giorgio, Fox, Bernard A, Gajewski, Thomas F, Ascierto, Paolo A
Publicado em 2012

NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug

Por Caporali, Simona, Levati, Lauretta, Graziani, Grazia, Muzi, Alessia, Atzori, Maria Grazia, Bonmassar, Enzo, Palmieri, Giuseppe, Ascierto, Paolo A, D’Atri, Stefania
Publicado em 2012